Kailera Therapeutics Inc.
- Address
- 890 Winter Street
Sponsor Overview
Specializations
Obesity Treatment
Kailera Therapeutics Inc. focuses on clinical research in obesity and overweight, with studies centered on changes in body weight and related metabolic outcomes.
- Weight reduction
- Body mass management
- Obesity without diabetes
Its research activity also includes participants with weight-related comorbidities and broader cardiometabolic risk profiles.
Metabolic Disease and Glycaemic Control
The sponsor’s trial portfolio includes people living with diabetes, with attention to changes in hemoglobin A1c alongside weight outcomes.
- HbA1c reduction
- Metabolic health
- Obesity with diabetes
This places glucose regulation and cardiometabolic disease among the key therapeutic interests in its clinical research program.
Comparative Efficacy in Anti-Obesity Therapy
Kailera Therapeutics evaluates its investigational anti-obesity therapy against established treatment options and placebo in weight-management studies.
- Comparative weight outcomes
- Therapeutic efficacy
- Standard-of-care comparison
The research emphasis includes treatment response in adults with obesity and associated metabolic conditions.
Weight-Related Comorbidities
The sponsor’s studies extend to obesity accompanied by weight-related comorbidities, reflecting interest in the broader clinical burden linked to excess adiposity.
- Comorbidity burden
- Overweight populations
- Metabolic risk
These trials address patients whose weight management needs are connected to additional health concerns beyond excess body weight alone.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 3 Study to Compare the Efficacy and Safety of KAI-9531 Versus Semaglutide in Participants Living with Obesity Without Diabetes |  Bulgaria Poland | Recruiting |
| Phase 3 Randomized Double-Blind Placebo-Controlled Study of KAI-9531 in Adults With Obesity or Overweight and Diabetes | Bulgaria Czechia Germany Hungary Poland Spain | Recruiting |
| Phase 3 Study of KAI-9531 in Adults With Obesity or Overweight With Weight-Related Comorbidities Without Diabetes | Bulgaria Czechia Germany Hungary Poland Spain | Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 81 sites across their trial portfolio.
Therapeutic Focus
- 1.Nutritional and Metabolic Diseases3 trials211 other sponsors
Partnered Research Centres
81 centres- Address
- Wilhelm-Leuschner-Platz 12, Zentrum-Süd, 04107 Leipzig
- Address
- Bazsalikom Utca 1/1, Borbanya, 4405 Nyiregyhaza
- Address
- Erzsebet Utca 11-13, 4025 Debrecen
- Address
- Ul. Ul. Jana Dlugosza 4, 51-162 Wroclaw
- Address
- Ul. Henryka Sienkiewicza 23, 30-033 Krakow
- Address
- Ul. Marymoncka 14/ U1 U2, 01-696 Warsaw
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Kailera Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.